NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
37 trialsNCT04983095 2026-02-17
METRO
Umeå University
Phase NA Recruiting
NCT03784755 2025-11-20
PLATON
Canadian Cancer Trials Group
Phase NA Active not recruiting
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT05242744 2025-07-11
FTT PET/CT in Metastatic Prostate Cancer
Abramson Cancer Center at Penn Medicine
Recruiting
NCT02913196 2025-05-23
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT05457699 2025-03-17
ANCHORProstate
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Recruiting
NCT03413995 2024-10-16
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04916613 2024-09-26
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER
Phase 3 Recruiting
NCT02825628 2024-08-29
CRPC
DexTech Medical AB
Phase 2 Completed
NCT03850795 2024-08-19
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc.
Phase 3 Terminated
NCT05563558 2024-06-11
PEAPOD_FOS
Fundacion Oncosur
Phase 2 Recruiting
NCT04028388 2024-04-17
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Phase 2 Completed
NCT06251492 2024-02-20
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Fudan University
Phase 2 Unknown
NCT05567770 2023-08-24
ACTION
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT03223727 2023-04-18
ROTOR
The Netherlands Cancer Institute
Completed
NCT05627778 2022-11-28
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03434158 2022-11-03
IMANOL
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT05530395 2022-09-14
BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC
University Hospital Virgen de las Nieves
Unknown
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT02814968 2022-04-14
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02815033 2022-04-14
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT03646162 2021-12-03
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Veru Inc.
Phase 2 Completed
NCT05078151 2021-10-14
iPROMET
Vall d'Hebron Institute of Oncology
Phase NA Unknown
NCT03024216 2021-05-26
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
University of Hawaii
Phase 1 Completed
NCT02407054 2021-05-11
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT04660617 2021-05-11
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
West China Hospital
Unknown
NCT04824937 2021-04-01
Telaglenastat + Talazoparib In Prostate Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT04603833 2021-02-21
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT02964988 2019-10-15
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Rigshospitalet, Denmark
Phase 2 Terminated
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT03414437 2019-03-19
Post-eRADicAte
Carolina Research Professionals, LLC
Unknown
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT02378870 2016-06-30
A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC
DexTech Medical AB
Phase 2 Terminated
NCT02074137 2016-06-02
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed